Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abbas Sarah, Ferreira Pamela C L, Bellaver Bruna, Povala Guilherme, Rohden Francieli, Aguzzoli Cristiano Schaffer, Zalzale Hussein, Ferrari-Souza João Pedro, Leffa Douglas T, Lussier Firoza Z, Soares Carolina, Bauer-Negrini Guilherme, Oliveira-Junior Markley Silva, Rodrigues Matheus Scarpatto, Saha Pampa, Ruppert Emma, Medeiros Marina Scop, Tissot Cécile, Therriault Joseph, Rahmouni Nesrine, Servaes Stijn, Benedet Andrea L, Ashton Nicholas J, Tudorascu Dana L, Gauthier Serge, Karim Helmet, Hong Chang Hyung, Roh Hyun Woong, Zimmer Eduardo R, Karikari Thomas K, Zetterberg Henrik, Blennow Kaj, Saeed Anum, Son Sang Joon, Rosa-Neto Pedro, Pascoal Tharick, for Alzheimer’s Disease Neuroimaging Initiative
Аннотация
OBJECTIVE: To evaluate the potential use of plasma GFAP changes as a secondary endpoint in Alzheimer's disease trials.
METHODS: We longitudinally evaluated plasma GFAP in individuals with amyloid-beta (Aβ)-PET scans at baseline in three well-characterized cohorts. Cox proportional hazards regression tested the association between changes in plasma GFAP and cognitive function. Analysis of the 95 % confidence interval of annualized change in plasma GFAP provided statistical inference for a significant longitudinal change. Effect size was calculated as the group mean divided by the standard deviation (SD). We estimated the sample size needed to test a 25% drug effect with 80% power on reducing changes in GFAP.
RESULTS: We assessed 487 individuals [176 cognitively unimpaired (CU; 29% Aβ positive) and 311 cognitively impaired (CI; 51% Aβ positive)] with some degree of cerebrovascular disease (Fazekas 1-3), over a mean (SD) follow-up of 1.84 (0.46) years. Changes in plasma GFAP were significantly associated with worsening in Clinical Dementia Rating sum of boxes (CDR-SB) score across the population (p < 0.0001). In CU, only Aβ positive individuals showed significant changes in GFAP (p < 0.001). On the other hand, both CI Aβ positive and negative individuals showed longitudinal progression in GFAP levels (p < 0.0001). The effect size of changes in plasma GFAP was higher in CU Aβ positive (0.44), followed by CI Aβ positive (0.42) and CI Aβ negative (0.38). Clinical trials focusing on CU Aβ positive would require 1320 individuals per study arm, while focusing on CI Aβ positive would require 1440 individuals per study arm.
CONCLUSION: Plasma GFAP increased in parallel with cognitive decline, making it a candidate for monitoring disease progression in trials aimed at mitigating cognitive deterioration. Although Aβ positivity significantly accelerated GFAP progression, the fact that GFAP was increased in CI Aβ negative with cerebrovascular disease supports its potential use as a secondary endpoint in this population as well.